8-K: American Shared Hospital Services Reports Q3 2026 Results

American Shared Hospital Services announced third quarter and nine-month 2026 financial results, highlighting revenue growth driven by Direct Patient Services, but also reporting net losses and decreased Adjusted EBITDA.

Summary

• American Shared Hospital Services reported third quarter 2026 revenue of $7.6 million, a 6.3% increase year-over-year, driven by a 13.6% rise in Direct Patient Services revenue to $4.6 million.
• For the first nine months of 2026, total revenue grew 13.7% to $23.1 million, with Direct Patient Services revenue up 27.0% to $13.5 million.
• The company generated $5.8 million in cash from operating activities in the first nine months of 2026, leading to an increase in cash, cash equivalents, and restricted cash to approximately $9.5 million as of September 30, 2026.
• Despite revenue growth, the company reported a net loss attributable to American Shared Hospital Services of $620,000 for Q3 2026 and $1.7 million for the nine-month period.
• Adjusted EBITDA decreased to $1.4 million in Q3 2026 from $1.9 million in Q3 2025, and for the nine-month period, it decreased to $3.8 million from $4.6 million.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed financial report. While revenue and cash flow show positive trends, the company continues to report net losses and a decrease in Adjusted EBITDA, indicating ongoing financial challenges.

Positives

• Total revenue for the third quarter increased by 6.3% to $7.6 million.
• Direct Patient Services segment revenue increased by 13.6% to $4.6 million in Q3 2026.
• Nine-month total revenue increased by 13.7% to $23.1 million.
• Nine-month Direct Patient Services revenue increased by 27.0% to $13.5 million.
• Generated $5.8 million in cash from operating activities during the first nine months of 2026.
• Cash, cash equivalents, and restricted cash increased to approximately $9.5 million as of September 30, 2026, up from $3.7 million at December 31, 2025.
• The company is advancing its joint venture with Hospital San Javier in Guadalajara, Mexico, with expected patient treatments to begin in mid-2027.
• Completed the upgrade of its Peru facility to a Gamma Knife Esprit system in June 2025, improving treatment times and capacity.

Negatives

• Reported a net loss attributable to American Shared Hospital Services of $620,000 for the third quarter of 2026, compared to a net loss of $17,000 in the prior-year period.
• Reported a net loss attributable to American Shared Hospital Services of $1.7 million for the first nine months of 2026, compared to a net loss of $922,000 in the prior-year period.
• Adjusted EBITDA for the third quarter decreased to $1.4 million from $1.9 million in the prior year.
• Adjusted EBITDA for the nine-month period decreased to $3.8 million from $4.6 million in the prior year.
• Total costs of revenue increased to $6.1 million in Q3 2026 from $5.6 million in Q3 2025.
• Selling and administrative expenses increased to $1.8 million in Q3 2026 from $1.5 million in Q3 2025, largely due to expenses related to the Third Amendment to the Credit Agreement.
• Medical Equipment Leasing segment revenue decreased by 3.1% in Q3 2026.
• Domestic Gamma Knife procedure volume was lower than the prior-year period due to contract expiration.

Risks

• Risks of economic and market conditions.
• Risk of compliance with debt covenants.
• Risks of variability of financial results between quarters.
• Risks of the Gamma Knife and proton beam radiation therapy and direct patient care services businesses.
• Risks of changes to Centers for Medicare & Medicaid Services reimbursement rates or reimbursement methodology.
• Risks of the timing, financing, and operations of the Company's Gamma Knife, PBRT, and direct patient care services businesses.
• Risk of expanding within or into new markets.
• Risk that current and future acquisitions could adversely affect financial results.

Future Outlook

The company is focused on improving operational performance, managing expenses, and maximizing facility contributions. Initiatives are underway to strengthen the financial position and support operations. The joint venture with Hospital San Javier is expected to extend Gamma Knife presence into a new market, with patient treatments anticipated to begin in mid-2027.

Management Comments

• "During the third quarter, we continued to make progress in growing our Direct Patient Services business, with revenue in this segment increasing 14% year over year."
• "While we continue to optimize our cost structure, we remain focused on improving operational performance, managing expenses, and maximizing the contribution of our existing facilities."
• "We are also continuing to advance initiatives intended to strengthen our financial position and support the Company's operations."
• "Overall, we are pleased with the progress we are making and remain keenly focused on enhancing our overall performance and shareholder value."
• "Our strategy remains focused on building a differentiated platform of advanced radiation therapy technologies and services that address the growing demand for precision cancer treatment."
• "As we continue to evaluate our capital structure strategies, our underlying operating business is demonstrating encouraging progress."
• "Our priorities remain focused on improving operational performance, increasing utilization across our existing network, expanding access to advanced radiation therapy services and strengthening our financial position."

Industry Context

StockSavvy.ai notes that American Shared Hospital Services operates in the growing field of precision cancer treatment, specifically stereotactic radiosurgery and radiation therapy. The company's focus on Direct Patient Services and international expansion aligns with industry trends towards specialized, high-volume treatment centers. However, the reported net losses and decreased Adjusted EBITDA suggest challenges in translating revenue growth into profitability, a common concern for companies in capital-intensive healthcare sectors.

Comparison to Industry Standards

• The company's revenue growth in Direct Patient Services (14% in Q3, 27% YTD) outpaces general healthcare sector growth, indicating strong performance in its niche.
• However, the continued net losses and declining Adjusted EBITDA are concerning when compared to industry peers who are often focused on achieving profitability and positive cash flow from operations.
• The increase in cash from operations is a positive sign, but the overall cash balance of $9.5 million may still be considered modest for a company with significant capital expenditures and debt obligations.
• Competitors like Varian Medical Systems (now part of Siemens Healthineers) and Elekta focus on technology development and sales, while AMS emphasizes service provision and equipment leasing, a different business model that requires careful cost management to achieve profitability.

Legal Proceedings

• Expenses associated with the Third Amendment to the Credit Agreement with Fifth Third Bank, executed in July 2026, are noted as increasing selling and administrative expenses.

Related Party Transactions

• Secured $2.0 million of subordinated financing from RCS/TIG Holdings LLC, an entity controlled by the Company's Executive Chairman, as part of the Third Amendment to the Credit Agreement.

Stakeholder Impact

• Shareholders may be concerned by the continued net losses and decreased Adjusted EBITDA, despite revenue growth.
• Creditors may be impacted by the company's ongoing efforts to strengthen its financial position and explore capital structure alternatives.
• Employees and customers may be affected by the company's focus on operational efficiency and expansion initiatives.

Next Steps

• Continue to optimize cost structure and improve operational performance.
• Maximize the contribution of existing facilities.
• Advance initiatives to strengthen financial position and support operations.
• Advance the joint venture initiative with Hospital San Javier in Guadalajara, Mexico, with expected patient treatments to begin in mid-2027.
• Continue to evaluate capital structure strategies.
• Pursue strategic opportunities for sustainable long-term growth and shareholder value.

Key Dates

Recommendation

The company shows positive revenue and cash flow generation trends, particularly in its Direct Patient Services segment, and is making progress on strategic initiatives like the Mexico joint venture. However, the persistent net losses, declining Adjusted EBITDA, and increased administrative expenses related to financing present significant headwinds. A 'hold' recommendation reflects the balance between potential growth drivers and ongoing financial challenges, suggesting investors should await clearer signs of sustained profitability before considering a buy.

Keywords

stereotactic radiosurgery, radiation therapy, cancer treatment, Gamma Knife, Proton Beam Radiation Therapy, Direct Patient Services, medical equipment leasing, healthcare services